Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Gum bacteria and Alzheimer’s: A hypothesis inches forward

Key clinical point: An agent against a common oral bacteria was seen reducing some markers of Alzheimer’s disease (AD).

Major finding: CSF levels of an AD-associated apolipoprotein E (ApoE) fragment and serum levels of RANTES, a chemokine associated with chronic inflammation, were reduced from baseline by about one-third in treated subjects, compared with placebo subjects (P less than .05).

Study details: A small, placebo-controlled trial enrolling nine subjects with mild to moderate AD.

Disclosures: Cortexyme, the maker of the experimental antimicrobial drug, sponsored the study, and 9 of the study’s 11 authors were employees.

Citation:

FROM AAIC 2019